Sign Out
Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children (see Precautions and Pharmacology: Pharmacodynamics under Actions).
The demonstration of the benefit of Ziagen is mainly based on results of studies performed in treatment-naïve adult patients on combination therapy with a twice daily regimen (see Pharmacology: Pharmacodynamics under Actions).
Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see Hypersensitivity reaction under Warnings). Abacavir should not be used in patients known to carry the HLA-B*5701 allele.
